Literature DB >> 8270254

Detection of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis.

X F Gu1, F de Rooij, G Voortman, K Te Velde, J C Deybach, Y Nordmann, B Grandchamp.   

Abstract

Acute intermittent porphyria (AIP) is an autosomal dominant disease characterized by mutations of the gene coding for porphobilinogen deaminase (PBGD). Until now, sixteen different mutations have been described. In an effort to investigate further the molecular epidemiology of AIP, we have undertaken a systematic study of different exons of the PBGD gene from a large number of unrelated patients. Here, we have examined seven of the fifteen exons of the gene from 43 unrelated Dutch and French AIP patients using denaturing gradient gel electrophoresis after polymerase chain reaction amplification. Eleven new mutations were found, accounting for the enzymatic defect in about half of the patients. This study further documents the molecular heterogeneity of the mutations responsible for AIP and describes an efficient strategy to detect the mutations in patients with previously unknown abnormalities.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8270254     DOI: 10.1007/bf00218912

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  22 in total

1.  Structure of porphobilinogen deaminase reveals a flexible multidomain polymerase with a single catalytic site.

Authors:  G V Louie; P D Brownlie; R Lambert; J B Cooper; T L Blundell; S P Wood; M J Warren; S C Woodcock; P M Jordan
Journal:  Nature       Date:  1992-09-03       Impact factor: 49.962

2.  Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support.

Authors:  T Hultman; S Ståhl; E Hornes; M Uhlén
Journal:  Nucleic Acids Res       Date:  1989-07-11       Impact factor: 16.971

3.  Molecular heterogeneity of acute intermittent porphyria: identification of four additional mutations resulting in the CRIM-negative subtype of the disease.

Authors:  M H Delfau; C Picat; F De Rooij; G Voortman; J C Deybach; Y Nordmann; B Grandchamp
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

4.  Denaturing gradient gel electrophoresis for rapid detection of latent carriers of a subtype of acute intermittent porphyria with normal erythrocyte porphobilinogen deaminase activity.

Authors:  F Bourgeois; X F Gu; J C Deybach; M P Te Velde; F de Rooij; Y Nordmann; B Grandchamp
Journal:  Clin Chem       Date:  1992-01       Impact factor: 8.327

5.  Detection and localization of single base changes by denaturing gradient gel electrophoresis.

Authors:  R M Myers; T Maniatis; L S Lerman
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  Acute intermittent porphyria: characterization of a novel mutation in the structural gene for porphobilinogen deaminase. Demonstration of noncatalytic enzyme intermediates stabilized by bound substrate.

Authors:  R J Desnick; L T Ostasiewicz; P A Tishler; P Mustajoki
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase.

Authors:  B Grandchamp; C Picat; R Kauppinen; V Mignotte; L Peltonen; P Mustajoki; P H Roméo; M Goossens; Y Nordmann
Journal:  Eur J Clin Invest       Date:  1989-10       Impact factor: 4.686

8.  High prevalence of a point mutation in the porphobilinogen deaminase gene in Dutch patients with acute intermittent porphyria.

Authors:  X F Gu; F de Rooij; J S Lee; K Te Velde; J C Deybach; Y Nordmann; B Grandchamp
Journal:  Hum Genet       Date:  1993-03       Impact factor: 4.132

9.  DNA polymorphism of human porphobilinogen deaminase gene in acute intermittent porphyria.

Authors:  D H Llewellyn; G H Elder; N A Kalsheker; O W Marsh; P R Harrison; B Grandchamp; C Picat; Y Nordmann; P H Romeo; M Goossens
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

10.  Detection of seven point mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria, by direct sequencing of in vitro amplified cDNA.

Authors:  C S Mgone; W G Lanyon; M R Moore; J M Connor
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

View more
  8 in total

1.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

Review 2.  Clinical features in 27 patients with Angelman syndrome resulting from DNA deletion.

Authors:  A Smith; C Wiles; E Haan; J McGill; G Wallace; J Dixon; R Selby; A Colley; R Marks; R J Trent
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

3.  Heteroduplex analysis detects frameshift and point mutations in patients with acute intermittent porphyria.

Authors:  W E Schreiber; F Fong; B A Nassar; A Jamani
Journal:  Hum Genet       Date:  1995-08       Impact factor: 4.132

4.  Acute intermittent porphyria: identification and expression of exonic mutations in the hydroxymethylbilane synthase gene. An initiation codon missense mutation in the housekeeping transcript causes "variant acute intermittent porphyria" with normal expression of the erythroid-specific enzyme.

Authors:  C H Chen; K H Astrin; G Lee; K E Anderson; R J Desnick
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 5.  Porphobilinogen deaminase gene structure and molecular defects.

Authors:  J C Deybach; H Puy
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

6.  Four mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria.

Authors:  G Lundin; J Hashemi; Y Floderus; S Thunell; E Sagen; A Laegreid; W Wassif; T Peters; M Anvret
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

Review 7.  Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Authors:  Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

8.  Characterization of porphobilinogen deaminase mutants reveals that arginine-173 is crucial for polypyrrole elongation mechanism.

Authors:  Helene J Bustad; Juha P Kallio; Mikko Laitaoja; Karen Toska; Inari Kursula; Aurora Martinez; Janne Jänis
Journal:  iScience       Date:  2021-02-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.